首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats
【24h】

CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats

机译:CS-3150,一种新型非甾体盐皮质激素受体拮抗剂,对乙酸脱氧皮质酮/盐诱导的高血压大鼠肾损伤具有预防和治疗作用

获取原文
获取原文并翻译 | 示例
           

摘要

The present study was designed to assess both preventive and therapeutic effects of (S)-1-(2-Hydroxyethyl)-4-methyl-N-[ 4( methylsulfonyl) phenyl]-5-[ 2-(trifluoromethyl) phenyl]-1H-pyrrole-3- carboxamide (CS-3150), a novel nonsteroidal mineralocorticoid receptor antagonist, on renal injury in deoxycorticosterone acetate (DOCA)/salt-induced hypertensive rats (DOCA rats). From 7 weeks of age, DOCA was subcutaneously administered once a week for 4 weeks to uninephrectomized rats fed a high-salt diet. In experiment 1, CS-3150 (0.3-3 mg/kg) was orally administered once a day for 4 weeks coincident with DOCA administration. In experiment 2, after establishment of renal injury by 4 weeks of DOCA/salt loading, CS-3150 (3 mg/kg) was orally administered once a day for 4 weeks with or without continuous DOCA administration. In experiment 1, DOCA/salt loading significantly increased systolic blood pressure (SBP), which was prevented by CS-3150 in a dose-dependent manner. Development of renal injury (proteinuria, renal hypertrophy, and histopathological changes in glomeruli and tubule) was also suppressed by CS-3150 with inhibition of mRNA expression of fibrosis, inflammation, and oxidative stress markers. In experiment 2, under continuous DOCA treatment, CS-3150 clearly ameliorated existing renal injury without lowering SBP, indicating that CS-3150 regressed renal injury independent of its antihypertensive action. Moreover, CS-3150 treatment in combination with withdrawal of DOCA showed further therapeutic effect on renal injury accompanied by reduction in SBP. These results demonstrate that CS-3150 not only prevents but also ameliorates hypertension and renal injury in DOCA rats. Therefore, CS-3150 could be a promising agent for the treatment of hypertension and renal disorders, and may have potential to promote regression of renal injury.
机译:本研究旨在评估(S)-1-(2-羟乙基)-4-甲基-N- [4(甲基磺酰基)苯基] -5- [2-(三氟甲基)苯基]-的预防和治疗作用1H-吡咯-3-羧酰胺(CS-3150),一种新型的非甾体盐皮质激素受体拮抗剂,对醋酸脱氧皮质酮(DOCA)/盐诱导的高血压大鼠(DOCA大鼠)的肾损伤。从7周大起,将DOCA每周一次皮下给药至喂食高盐饮食的未切除子宫的大鼠,持续4周。在实验1中,每天一次口服CS-3150(0.3-3 mg / kg),持续4周,与DOCA给药同时进行。在实验2中,在通过DOCA /盐负荷4周建立肾脏损伤后,每天口服CS-3150(3 mg / kg),持续4周,无论是否连续给予DOCA。在实验1中,DOCA /盐负荷显着增加了收缩压(SBP),CS-3150则以剂量依赖的方式阻止了收缩压的升高。 CS-3150还抑制了肾损伤(蛋白尿,肾肥大以及肾小球和肾小管的组织病理学变化)的发展,并抑制了纤维化,炎症和氧化应激标志物的mRNA表达。在实验2中,在持续的DOCA治疗下,CS-3150明显改善了现有的肾脏损伤而没有降低SBP,这表明CS-3150可以独立于其降压作用而退缩肾脏损伤。此外,CS-3150疗法与DOCA撤药相结合对肾损伤伴有SBP降低显示出进一步的治疗作用。这些结果表明,CS-3150不仅可以预防而且可以改善DOCA大鼠的高血压和肾损伤。因此,CS-3150可能是治疗高血压和肾脏疾病的有前途的药物,并且可能具有促进肾损伤消退的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号